Fusion Pharmaceuticals Inc. Proceeds from Stock Options Exercised
Fusion Pharmaceuticals Inc. reported Proceeds from Stock Options Exercised of $627.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2024-05-07
- Fusion Pharmaceuticals Inc. proceeds from stock options exercised for the quarter ending 2024-03-31 was $627.00K.
- Fusion Pharmaceuticals Inc. proceeds from stock options exercised for the quarter ending 2022-06-30 was $79.00K, a 62.38% decline year-over-year.
- Fusion Pharmaceuticals Inc. proceeds from stock options exercised for the quarter ending 2022-03-31 was $82.00K, a 36.92% decline year-over-year.
- Fusion Pharmaceuticals Inc. proceeds from stock options exercised for the quarter ending 2021-06-30 was $210.00K.
- Fusion Pharmaceuticals Inc. proceeds from stock options exercised for fiscal 2020 was $56.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|
| 2024-03-31 | $627.00K 10-Q · filed 2024-05-07 | ||
| 2023-06-30 | $11.00K 10-Q · filed 2023-08-08 | ||
| 2022-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $161.00K 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $82.00K 10-Q · filed 2023-05-11 | ||
| 2021-06-30 | $210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $340.00K 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $130.00K 10-Q · filed 2022-05-10 | ||
| 2020-12-31 | $56.00K 10-K · filed 2021-03-25 |